During the last session, Caladrius Biosciences Inc. (NASDAQ:CLBS)’s traded shares were 0.31 million, with the beta value of the company hitting 0.96. At the end of the trading day, the stock’s price was $0.51, reflecting an intraday loss of -1.94% or -$0.01. The 52-week high for the CLBS share is $1.34, that puts it down -162.75 from that peak though still a striking 21.57% gain since the share price plummeted to a 52-week low of $0.40. The company’s market capitalization is $31.30M, and the average intraday trading volume over the past 10 days was 0.18 million shares, and the average trade volume was 170.40K shares over the past three months.
Caladrius Biosciences Inc. (CLBS) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. CLBS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.1.
Caladrius Biosciences Inc. (NASDAQ:CLBS) trade information
Caladrius Biosciences Inc. (CLBS) registered a -1.94% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.94% in intraday trading to $0.51 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 1.90%, and it has moved by -11.82% in 30 days. Based on these gigs, the overall price performance for the year is -60.49%. The short interest in Caladrius Biosciences Inc. (NASDAQ:CLBS) is 0.54 million shares and it means that shorts have 4.49 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.50, which implies an increase of 88.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.00 and $6.00 respectively. As a result, CLBS is trading at a discount of -1076.47% off the target high and -488.24% off the low.
Caladrius Biosciences Inc. (CLBS) estimates and forecasts
Statistics show that Caladrius Biosciences Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Caladrius Biosciences Inc. (CLBS) shares have gone down -30.18% during the last six months, with a year-to-date growth rate more than the industry average at 20.00% against 1.00.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 36.30%. While earnings are projected to return 5.90% in 2022.
Caladrius Biosciences Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Caladrius Biosciences Inc. (NASDAQ:CLBS)’s Major holders
Caladrius Biosciences Inc. insiders own 2.74% of total outstanding shares while institutional holders control 18.51%, with the float percentage being 19.03%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 42 institutions own stock in it. As of Mar 30, 2022, the company held over 2.69 million shares (or 4.45% of all shares), a total value of $1.94 million in shares.
The next largest institutional holding, with 2.37 million shares, is of Sabby Management, LLC’s that is approximately 3.92% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $1.71 million.
Also, the Mutual Funds coming in first place with the largest holdings of Caladrius Biosciences Inc. (CLBS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 1.78 million shares. This amounts to just over 2.93 percent of the company’s overall shares, with a $1.28 million market value. The same data shows that the other fund manager holds slightly less at 0.85 million, or about 1.41% of the stock, which is worth about $0.61 million.